Drugs / GSK 5733584
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01042379 | Mar 2010 → Dec 2030 expected | HER2 positive breast carcinoma, angiosarcoma, female breast carcinoma, hormone receptor-positive breast cancer +1 | QuantumLeap Healthcare Collaborative | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 7
| Date | Issuer | Release |
|---|---|---|
| 2026-03-02 | Hansoh BioMedical R&D Company | Results ESGO 2026 | 翰森制药Mocertatug Rezetecan（B7-H4 ADC）治疗铂敏感复发卵巢癌研究数据发布，其中一项研究入选LBA hansoh.cn ↗
Mocertatug rezetecan作为单药治疗及与贝伐珠单抗联合用药，在重度经治的铂敏感复发卵巢癌（PSOC）患者中显示出抗肿瘤活性，安全性可控. |
| 2026-02-28 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Results ESGO 2026 | HANSOH PHARMA PRESENTED DATA FOR MOCERTATUG REZETECAN (HS-20089,A B7-H4-TARGETED ADC) IN PATIENTS WITH PLATINUM-SENSITIVE OVARIAN CANCER,WITH ONE STUDY SELECTED AS LBA hspharm.com ↗
Across the two studies, mocertatug rezetecan showed anti-tumor activity with a safety profile consistent with previous studies. |
| 2025-11-11 | Hansoh BioMedical R&D Company | Results IGCS | 翰森制药B7-H4 ADC治疗铂耐药卵巢癌Ⅱ期研究结果入选口头报告 hansoh.cn ↗
本次大会的研究结果显示，截至数据截止日期（2025年6月20日）， HS-20089在未筛选B7-H4表达的情况下，在经多线治疗失败的铂耐药卵巢癌（PROC）患者中展现出令人鼓舞的疗效. |
| 2025-11-10 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Results HANSOH PHARMA ANNOUNCES ORAL PRESENTATION OF PHASE 2 STUDY FINDINGS OF HS-20089 (B7-H4 ADC) IN PLATINUM-RESISTANT OVARIAN CANCER AT IGCS 2025 hspharm.com ↗
As of the June 20, 2025 data cutoff, HS-20089 is the first B7-H4 ADC to demonstrate promising efficacy in heavily pretreated patients with platinum-resistant ovarian cancer (PROC) who were not selected based on tumor B7-H4 expression. |
| 2025-10-20 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Results ESMO 2025 | HANSOH PHARMA PRESENTS THE PHASE 2 STUDY FINDINGS OF HS-20089 (B7-H4-TARGETED ADC), IN PATIENTS WITH PLATINUM-RESISTANT OVARIAN CANCER (PROC) hspharm.com ↗
HS-20089 (licensed to GSK as GSK5733584) is the first B7-H4-directed antibody-drug conjugate (ADC) to demonstrate promising efficacy in heavily pretreated patients with platinum-resistant ovarian cancer (PROC) who were not selected based on tumor B7-H4 expression, with a confirmed ORR of 48.5% and DoR of 6.8 months，a median PFS (mPFS) of 6.4 months and a mOS of 14.6 months at the dose of 4.8mg/kg. |
| 2025-10-20 | Hansoh BioMedical R&D Company | Results ESMO | 翰森制药HS-20089(B7-H4 ADC)用于铂耐药卵巢癌（PROC）患者治疗的Ⅱ期研究结果发布 hansoh.cn ↗
HS-20089注射液在PROC患者中显示出良好的疗效，确认的客观缓解率（ORR）为48. 5%，缓解持续时间（DoR）为6. 8个月，中位无进展生存期（mPFS）为6. 4个月，中位总生存期（mOS）为14. 6个月. |
| 2025-05-02 | Hansoh BioMedical R&D Company | Regulatory 翰森制药B7-H4 ADC获NMPA纳入突破性治疗药物，用于铂耐药卵巢癌治疗 hansoh.cn ↗
注射用HS-20089获国家药品监督管理局（NMPA）批准纳入“突破性治疗药物” |
All press releases naming this drug 7 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK 5733584 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01042379 ↗ |
| Route | Intravenous | “Route: Intravenous infusion Dosage Form: 4.8 mg/kg intravenous” NCT01042379 ↗ |